Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
ESR1 and intellectual disability are reported together in 2 articles.
Gene
ESR1
- HGNC
- HGNC:3467
52articles
52mentions
9variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 22lung cancer 4diabetes mellitus 2intellectual disability 2Alzheimer disease 1COVID-19 1Parkinson disease 1colorectal cancer 1
Reported variants (articles · ClinVar status)
Phenotype
Intellectual disability
- HPO
- HP:0001249
736articles
736mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Targeted drug delivery of oxazolidine derivative AP9 using chitosan nanoparticles for neuroprotection in a BPA-induced zebrafish model.
PMID 42175962 | DOI 10.1080/1061186X.2026.2678325 · Journal of drug targeting · 2026 · 8 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ESR1 | “Network pharmacology and molecular docking identified AP9 as a lead chemical with high affinity for hub proteins: as AKT1, EGFR, ESR1, HIF1A, MTOR, and PARP1, implying an involvement in neurodegenerative disease pathways.” | 0.98 | hgnc_dict_v1 |
| phenotype | intellectual disability | “Behavioural assays showed that AP9-Ch reduced BPA-induced anxiety-like behaviour, aggression, and cognitive impairment, as demonstrated by improved performance in open field, novel tank diving, mirror biting, and T-maze testing.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | AKT1 | “Network pharmacology and molecular docking identified AP9 as a lead chemical with high affinity for hub proteins: as AKT1, EGFR, ESR1, HIF1A, MTOR, and PARP1, implying an involvement in neurodegenerative disease pathways.” | 0.98 | hgnc_dict_v1 |
| gene | EGFR | “Network pharmacology and molecular docking identified AP9 as a lead chemical with high affinity for hub proteins: as AKT1, EGFR, ESR1, HIF1A, MTOR, and PARP1, implying an involvement in neurodegenerative disease pathways.” | 0.98 | hgnc_dict_v1 |
Comparative Efficacy of Metformin and Glimepiride in Modulating Pharmacological Network to Increase BDNF Levels and Benefit Type 2 Diabetes-Related Cognitive Impairment.
PMID 38001940 | PMCID PMC10669717 | DOI 10.3390/biomedicines11112939 · Biomedicines · 2023 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ESR1 | “Whereas, glimepiride increases BDNF by binding to KCNJ11 via AP2M1 and ESR1 proteins.” | 0.98 | hgnc_dict_v1 |
| phenotype | intellectual disability | “Comparative Efficacy of Metformin and Glimepiride in Modulating Pharmacological Network to Increase BDNF Levels and Benefit Type 2 Diabetes-Related Cognitive Impairment.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | BDNF | “Comparative Efficacy of Metformin and Glimepiride in Modulating Pharmacological Network to Increase BDNF Levels and Benefit Type 2 Diabetes-Related Cognitive Impairment.” | 0.98 | hgnc_dict_v1 |
| gene | PRKAB1 | “Metformin stimulates BDNF via APP binding to the PRKAB1 receptor.” | 0.98 | hgnc_dict_v1 |